Gene: NRG2

9542
DON1|HRG2|NTAK
neuregulin 2
protein-coding
5q31.2
Ensembl:ENSG00000158458 MIM:603818 Vega:OTTHUMG00000129241 UniprotKB:O14511
NC_000005.10
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.807e-1 (AD)  6.041e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg19583819chr5:139283051NRG28.100e-12Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CLUH0.821
ACSF30.817
TMEM120B0.813
SCAP0.81
MTG20.803
MOK0.801
ZNF2820.801
PUS10.8
GALNS0.8
NLGN20.798

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.49
OR4F29-0.434
CTNNA3-0.403
TFPI2-0.376
GSDMA-0.37
CPA3-0.363
C2orf83-0.36
CD48-0.358
DNASE1L3-0.357
CNTF-0.357

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRG2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRG2 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of NRG2 mRNA22230336|2906747
D020106AcrylamideAcrylamide results in decreased expression of NRG2 mRNA28959563
D000643Ammonium ChlorideAmmonium Chloride affects the expression of NRG2 mRNA16483693
D001151ArsenicArsenic affects the expression of NRG2 protein24675094
D004958EstradiolEstradiol results in increased expression of NRG2 mRNA23373633
C006780bisphenol Abisphenol A results in decreased expression of NRG2 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of NRG2 gene28505145
D003300Copper[Copper co-treated with Dietary Sucrose] results in increased expression of NRG2 mRNA26033743
D003300CopperCopper deficiency results in increased expression of NRG2 mRNA26033743
D016572CyclosporineCyclosporine results in decreased expression of NRG2 mRNA20106945
C010902decabromobiphenyl etherdecabromobiphenyl ether results in increased expression of NRG2 mRNA23914054
D019422Dietary Sucrose[Copper co-treated with Dietary Sucrose] results in increased expression of NRG2 mRNA26033743
D019422Dietary SucroseDietary Sucrose results in increased expression of NRG2 mRNA26033743
D002117CalcitriolCalcitriol results in decreased expression of NRG2 mRNA16002434
D004397FonofosFonofos results in increased methylation of NRG2 promoter22847954
C069837fullerene C60fullerene C60 results in decreased expression of NRG2 mRNA19167457
D008345ManganeseManganese results in increased expression of NRG2 mRNA17175027
C025340manganese chloridemanganese chloride results in increased expression of NRG2 mRNA17175027
D008558MelphalanMelphalan results in decreased expression of NRG2 mRNA22363485
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of NRG2 mRNA28001369
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of NRG2 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of NRG2 mRNA"25554681
D009532NickelNickel results in decreased expression of NRG2 mRNA24768652|2558310
C028007nickel monoxidenickel monoxide results in increased expression of NRG2 mRNA19167457
D010278ParathionParathion results in increased methylation of NRG2 promoter22847954
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of NRG2 mRNA19710929
D010936Plant ExtractsPlant Extracts results in decreased expression of NRG2 mRNA23557933
D011192Potassium DichromatePotassium Dichromate results in decreased expression of NRG2 mRNA23608068
D011441PropylthiouracilPropylthiouracil results in decreased expression of NRG2 mRNA24780913
D020849Raloxifene HydrochlorideRaloxifene Hydrochloride results in increased expression of NRG2 mRNA15849065
C012568terbufosterbufos results in increased methylation of NRG2 promoter22847954
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in decreased expression of NRG2 mRNA28065790
D014303TrinitrotolueneTrinitrotoluene affects the expression of NRG2 mRNA21346803
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of NRG2 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of NRG2 mRNA26272509
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRG2 mRNA"27188386
C111237vorinostatvorinostat results in increased expression of NRG2 mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004713protein tyrosine kinase activity-TAS-  
GO:0005088Ras guanyl-nucleotide exchange factor activity-TAS-  
GO:0005102signaling receptor binding-IBA21873635  
GO:0005102signaling receptor binding-TAS9168114  
GO:0008083growth factor activity-IEA-  
GO:0046934phosphatidylinositol-4,5-bisphosphate 3-kinase activity-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000165MAPK cascade-TAS-  
GO:0007165signal transduction-TAS9168114  9168115  
GO:0010469regulation of signaling receptor activity-IEA-  
GO:0018108peptidyl-tyrosine phosphorylation-IEA-  
GO:0035556intracellular signal transduction-IBA21873635  
GO:0038128ERBB2 signaling pathway-TAS-  
GO:0046854phosphatidylinositol phosphorylation-IEA-  
GO:0048513animal organ development-IBA21873635  
GO:0051897positive regulation of protein kinase B signaling-TAS-  
GO:2000145regulation of cell motility-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-TAS-  
GO:0005615extracellular space-IBA21873635  
GO:0005622intracellular-IEA-  
GO:0005886plasma membrane-IEA-  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
hsa04012ErbB signaling pathway
Reactome ID Reactome Term Evidence
R-HSA-1227986Signaling by ERBB2TAS
R-HSA-1227986Signaling by ERBB2IEA
R-HSA-1236394Signaling by ERBB4TAS
R-HSA-1236394Signaling by ERBB4IEA
R-HSA-1250196SHC1 events in ERBB2 signalingIEA
R-HSA-1250196SHC1 events in ERBB2 signalingTAS
R-HSA-1250342PI3K events in ERBB4 signalingTAS
R-HSA-1250347SHC1 events in ERBB4 signalingTAS
R-HSA-1251985Nuclear signaling by ERBB4IEA
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-1306955GRB7 events in ERBB2 signalingTAS
R-HSA-1358803Downregulation of ERBB2:ERBB3 signalingTAS
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-1643685DiseaseTAS
R-HSA-1963640GRB2 events in ERBB2 signalingTAS
R-HSA-1963642PI3K events in ERBB2 signalingTAS
R-HSA-199418Negative regulation of the PI3K/AKT networkTAS
R-HSA-2219528PI3K/AKT Signaling in CancerTAS
R-HSA-2219530Constitutive Signaling by Aberrant PI3K in CancerTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5673001RAF/MAP kinase cascadeTAS
R-HSA-5683057MAPK family signaling cascadesTAS
R-HSA-5684996MAPK1/MAPK3 signalingTAS
R-HSA-6785631ERBB2 Regulates Cell MotilityTAS
R-HSA-6811558PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingTAS
R-HSA-8847993ERBB2 Activates PTK6 SignalingTAS
R-HSA-8848021Signaling by PTK6TAS
R-HSA-8863795Downregulation of ERBB2 signalingTAS
R-HSA-9006925Intracellular signaling by second messengersTAS
R-HSA-9006927Signaling by Non-Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28722770Asbestos-associated genome-wide DNA methylation changes in lung cancer. (2017 Nov 15)Kettunen EInt J Cancer